[IRY] SPDR S&P International HealthCareSe

Overview

Type of security: Fund

Tags: Developed ex-US, Developed markets, Equity, ETF, ex-US, Global sectors, Health care, Index Based, International, Not Inversed, Regional, Sector, Stocks, Unleveraged

The data is delayed by 15 minutes.

 

Price: 42.97 Change: 0.12 (0.28%)
Ext. hours: Change: 0 (0%)

chart IRY

Refresh chart

Description: The investment seeks investment results that, before fees and expenses, correspond generally to the total return performance of an index that tracks the health care sector of developed global markets outside the United States. The fund employs a sampling strategy in seeking to track the performance of the S&P Developed Ex-U.S. BMI Health Care Sector Index. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index or in American Depositary Receipts ("ADRs") or Global Depositary Receipts ("GDRs") based on securities comprising the index.

See how to gain 20% in 14 sec with TrendsInvesting

Technical Data
High 52 week51.59 Low 52 week40.94 Last close49.99 Last change0%
RSI58.17 Average true range3.76 Beta0.51 Volume8.2 K
Simple moving average 20 days0.12% Simple moving average 50 days-0.56% Simple moving average 200 days8.23%
Performance Data
Performance Week0% Performance Month-0.2% Performance Quart3.15% Performance Half13.91%
Performance Year2.53% Performance Year-to-date16.61% Volatility daily0.49% Volatility weekly1.09%
Volatility monthly2.24% Volatility yearly7.75% Relative Volume218.71% Average Volume100.31 K
New High New Low
Funds Characteristics
30-day SEC yield Average market capitalization Average weighted market capitalization89.72 B Forward P/E17.47
Gross expense ratio Index dividend yield2.47 Median market cap Number of holdings120
Price to Book Value 3.18 Price to Earnings Total expense ratio0.5% Total net assets
Weighted market capitalization

Info

Characteristics:
NAME VALUE
Index Dividend Yield2.47
Fy1 P/E Ratio17.47
Number Of Holdings120
P/Bv Ratio3.18
Average Weighted Market Capitalization89724.88
Total Expense Ratio0.50
Top Holdings:
NAME VALUE
Novartis Ag12.05
Roche Holding Ltd Genusssch.8.78
Glaxosmithkline Plc6.89
Sanofi6.75
Bayer Ag5.85
Novo Nordisk A/s Class B5.17
Astrazeneca Plc4.83
Teva Pharmaceutical Industries Limited3.27
Roche Holding Ag2.87
Valeant Pharmaceuticals International Inc.2.77
Top Sectors:
NAME VALUE
Pharmaceuticals73.08
Health Care Equipment Supplies8.62
Health Care Providers Services6.89
Unassigned4.78
Biotechnology4.69
Life Sciences Tools Services1.74
Health Care Technology0.19
Top Countries:
NAME VALUE
Switzerland26.77
United Kingdom16.02
Japan14.73
Germany10.83
France9.01
Denmark6.91
Australia3.92
Canada3.48
Israel3.45
Sweden1.25
Spain1.07
Belgium0.86
New Zealand0.44
Singapore0.44
Finland0.39

News

2017-09-01 07:37:06 | Novartis on the Street: Analysts’ Recommendations after 2Q17

2017-05-01 10:39:07 | How Did GlaxoSmithKline’s HIV Business Perform in 1Q17?

2017-05-01 07:37:08 | Novartis’s Valuation after 1Q17 Earnings

2017-04-27 15:36:08 | Novartis’s 1Q17 Earnings: Segment Performances

2017-04-26 10:36:53 | Analyst Ratings and Recommendations for GlaxoSmithKline

2017-04-25 07:40:14 | GlaxoSmithKline’s 1Q17 Earnings: Analysts’ Estimates

2017-03-30 10:36:33 | What Wall Street Analysts Estimate for GlaxoSmithKline

2017-03-29 10:36:23 | Performance of GlaxoSmithKline’s HIV Business in 2016

2017-02-14 15:05:43 | Performance of GlaxoSmithKline’s Pharmaceuticals Segment in 4Q16

2017-02-03 09:06:16 | Why the Majority of Analysts Deem Novartis a ‘Buy’

2017-01-31 07:35:57 | Johnson & Johnson’s Valuation Cheat Sheet

2016-12-30 10:36:44 | A Look at GlaxoSmithKline’s HIV Business

2016-12-29 15:27:42 | How GlaxoSmithKline’s Valuation Compares to Its Peers’

2016-09-16 08:04:56 | Roche’s Oncology Wheelhouse Stacked with Competitive Drugs

2016-09-09 16:04:58 | GlaxoSmithKline’s Fundamentals Show It Has Lots of Room to Run

2016-05-14 09:01:00 | Foreign Stocks: Looking Beyond Index Valuations

2015-12-20 01:00:00 | Why These Investors Overhauled Their Portfolios

2015-12-14 13:20:55 | FEZ and EWJ Fall as Crude Oil Prices Plunge Further

2015-12-09 17:54:00 | DuPont-Dow Megadeal Talk Stirs Materials ETFs

2015-12-09 08:06:31 | Kite Pharma Leads IBB’s Mid-Caps on Its Zuma-1 Phase 1 Results

2015-12-08 18:56:00 | Oil ETFs Dig A Hole But Could Syria Change That?

2015-12-08 13:06:33 | Consumer Staples Didn’t Fall into Equity Market’s Downtrend

2015-12-08 13:03:47 | SPY Ended Negative as Oil Sank to New Lows

2015-12-08 12:07:52 | Alexion Tops IBB’s Large-Caps on Release of New Research Data

2015-12-07 18:13:00 | Jet ETF Climbs, Dow In Red For 2015 As Oil Weighs

2015-12-07 17:34:05 | Financial Sector Catches a Rate Hike Tailwind on December 4

2015-12-07 17:34:00 | Gung-Ho US Employment Scene Catapults SPY on December 4

2015-12-07 15:45:31 | How Are IBB’s American Depositary Receipts Performing?

2015-12-07 11:52:13 | FEZ Rises by 1.2% on Strong Employment Data

2015-12-07 07:05:36 | IHI’s Small Caps Outperformed the Market

2015-12-07 07:05:33 | Abiomed Rose 1% on High Trading Volume

2015-12-05 07:40:00 | These 3 ETFs Jumped in November

2015-12-04 18:23:00 | Gold Mining ETFs Spike As Metal Shines

2015-12-04 15:07:25 | Mallinckrodt Rose after Sale of Contrast Media & Delivery System

2015-12-04 14:06:29 | Rate Hike Hints Boost November Fund Flows of $731 Million in XLF

2015-12-04 07:00:00 | A Low-Cost Way to Bet on Banking

2015-11-25 11:12:07 | 3 Big Market Movers This Week

2015-11-05 19:47:28 | U.S.-based stock funds attract $5.7 bln in latest week -Lipper

2015-09-13 21:40:00 | Is The U.S. Economy Going To Crash This Year?